• No results found

18 results with keyword: 'safinamide for the treatment of parkinson s disease'

Safinamide: an add-on treatment for managing Parkinson’s disease

Randomized trial of safinamide add-on to levodopa in Parkinson’s disease with motor fluctuations. Borgohain R, Szasz J, Stanzione P,

Protected

N/A

11
0
0
2020
Investigational agents in the treatment of Parkinson's disease: focus on safinamide

Safinamide as monotherapy and as an adjunct to dopamine agonists improves Unified Parkinson’s Disease Rating Scale motor scores.. One randomized, placebo-controlled

Protected

N/A

6
0
0
2020
HPC Software Debugger and Performance Tools

Knobloch SC Introduction, November 2015 13 DDT: Main Window Process controls Process groups Source code Variables Expression evaluator Stack trace... DDT:

Protected

N/A

80
0
0
2021
Adjuvant therapies for Parkinson’s disease: critical evaluation of safinamide

Randomized, double-blind, placebo-controlled, dose- finding study Monotherapy or adjunct therapy to stable single DA 172 early PD patients (56 per group of treatment) Proportion

Protected

N/A

10
0
0
2020
Safinamide for the treatment of Parkinson's disease

Post hoc analysis showed the 100mg/day dose was associated with lowered intervention rate with dopamine therapy and improved UPDRS scores (secondary outcomes)

Protected

N/A

14
0
0
2021
(E) 5 Chloro 3 (2,6 di­chloro­benzyl­­idene)­indolin 2 one

The cell e.s.d.'s are taken into account individually in the estimation of e.s.d.'s in distances, angles and torsion angles; correlations between e.s.d.'s in cell parameters are

Protected

N/A

9
0
0
2020
Safinamide for the treatment of Parkinson's disease

Reduction of LD dose possible Few dropouts and no safety concerns SETTLE efficacy and safety of S (NCT00627640) [80,81] Phase III PC 24 weeks 549 50 100 Advanced PD: add-on therapy to

Protected

N/A

50
0
0
2021
The resurgence of neurotransmitter modulation in Parkinson’s disease with safinamide

Safinamide as an add-on therapy to a stable dose of a single dopamine agonist: results from a randomized, placebo-controlled, 24-week multicenter trial in early

Protected

N/A

7
0
0
2020
Speech treatment for Parkinson s disease

future investigations have the potential to further clar- ify underlying mechanisms of speech disorders in PD while addressing key variables for improving speech treatment

Protected

N/A

17
0
0
2021
Individual Life Insurance in Indonesia to 2019: Market Databook

- This report provides you with a breakdown of market data including data on number of active policies, gross written premiums and insurance penetration percentage.. - This

Protected

N/A

5
0
0
2021
Treatment of Parkinson s disease

Higher load of dopaminergic treatment may be related to the hallucinations, but disease severity, cognitive impairment, depression, older age and worse visual acuity may also

Protected

N/A

7
0
0
2021
Name: Class & Sec. Roll No.:

two valid reasons.. MHSS/ECO 12/MIDTERM-2019 Page 3 iii) Use the given information to answer the given questions.. Why total fixed cost curve in the diagram originates from A and

Protected

N/A

22
0
0
2021
Emerging approaches in Parkinson’s disease – adjunctive role of safinamide

Safinamide as an add­on therapy to a stable dose of a single dopamine agonist: results from a randomized, placebo­controlled, 24­week multicenter trial in early idio­ pathic

Protected

N/A

10
0
0
2020
Lessons From Down Under The D2C Market in Australia and what the UK can learn.

• suffers at least a 20% reduction in capacity to earn their pre-disability income, regardless as to whether they can or cannot perform any income producing duties, and is actually

Protected

N/A

33
0
0
2021
Preface. Manual Revisions. Trademarks

When the DIR-412 is in 3G router mode, LAN clients can access the DIR-412 via the DIR-412’s Ethernet connection, as well as via the wireless connection.... 7 D-Link DIR-412

Protected

N/A

101
0
0
2021
The Impact of FDI on the Economic Transition and Economic Development in Kosovo

- FDI in Kosovo in 2007 reached the highest amount of investment which in the years that followed came to halt, and according to the analysis of expected that in the coming years

Protected

N/A

8
0
0
2020
Zambon and US Worldmeds partner to bring Newron Pharmaceuticals Parkinson s disease treatment Xadago (safinamide) to the U.S.

This document contains forward-looking statements, including (without limitation) about (1) Newron’s ability to develop and expand its business, successfully complete development

Protected

N/A

5
0
0
2021
ALLERGIC RHINITIS IN EARLY INFANCY

Some infants with com- plete nasal obstruction will not open their mouths for breathing, and death from as- phyxia may result as has been reported in bilateral choanal atresia.6

Protected

N/A

7
0
0
2020

Upload more documents and download any material studies right away!